<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1208922/" ref="ordinalpos=4952&amp;ncbi_uid=623907&amp;link_uid=PMC1208922" image-link="/pmc/articles/PMC1208922/figure/F1/" class="imagepopup">Figure 1.  From: Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. </a></div><br /><div class="p4l_captionBody"><b>The EGFR/MAPK/ERK1/2 signaling pathway</b>. We have previously shown that sulindac metabolites inhibit both MEK1/2 and ERK1/2 activation. The goal of this study was to determine if this inhibition is due to downregulation of the EGFR.</div></div>